PMID- 15547716
OWN - NLM
STAT- MEDLINE
DCOM- 20050405
LR  - 20141120
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 25
IP  - 6
DP  - 2004 Dec
TI  - Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.
PG  - 1769-80
AB  - The HER2/neu protein is over-expressed in multiple epithelial tumors and the 
      source of immunogenic peptides currently under investigation in vaccine trials in 
      ovarian and breast cancers. We sought to define the correlation between HER2/neu 
      expression and risk for prostate cancer recurrence and then determine the 
      potential efficacy of anti-HER2/neu vaccination in prostate cancer patients at 
      risk for recurrence. The risk for prostate-specific antigen (PSA) recurrence in 
      95 patients undergoing prostatectomy at the Walter Reed Army Medical Center 
      (WRAMC) was calculated and correlated to HER2/neu expression, as determined by 
      immunohistochemical staining. Peripheral blood lymphocytes (PBL) were then 
      isolated from six consecutive human leukocyte antigen (HLA) A2+ patients with 
      HER2/neu+ prostate tumors. These PBL were grown in parallel cultures and 
      stimulated either with no peptide, HER2/neu E75 peptide, or control peptide. The 
      cultures were compared for stimulated proliferation, induced peptide-specific 
      cytotoxicity and tumor-specific cytotoxicity. When assessed by risk group, 69% of 
      the high risk patients' tumors over-expressed HER2/neu compared to 47% of the 
      intermediate risk group (p<0.05). Evaluation of the in vitro immune response of 
      PBL isolated from six consecutive prostate cancer patients revealed a 
      statistically significant increase in E75-stimulated lymphocytic proliferation. 
      E75-stimulated lymphocytes demonstrated an E75-specific cytolytic response in 6/6 
      prostate cancer patients that increased with successive stimulations. Moreover, 
      these E75-specific lymphocytes also demonstrated tumor-specific lysis against 
      HER2/neu-expressing prostate cancer cell lines. The majority of prostate cancer 
      patients at high risk for recurrence have HER2/neu expressing tumors. Hence, 
      HER2/neu is a viable target for immunotherapeutics such as preventative 
      immunization strategies with HER2/neu peptide vaccines.
FAU - Woll, Michael M
AU  - Woll MM
AD  - Divisions of General Surgery and Urology, Department of Surgery, Walter Reed Army 
      Medical Center, Washington, DC 20307, USA.
FAU - Hueman, Matthew T
AU  - Hueman MT
FAU - Ryan, Gayle B
AU  - Ryan GB
FAU - Ioannides, Constantin G
AU  - Ioannides CG
FAU - Henderson, Charles G
AU  - Henderson CG
FAU - Sesterhan, Isabelle A
AU  - Sesterhan IA
FAU - Shrivasta, Shiv
AU  - Shrivasta S
FAU - McLeod, David G
AU  - McLeod DG
FAU - Moul, Judd W
AU  - Moul JW
FAU - Peoples, George E
AU  - Peoples GE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Cancer Vaccines)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - *Cancer Vaccines
MH  - Cell Proliferation
MH  - *Gene Expression Profiling
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunotherapy
MH  - Male
MH  - Neoplasm Recurrence, Local/*genetics
MH  - Prostatic Neoplasms/*genetics/*therapy
MH  - Receptor, ErbB-2/*genetics
MH  - Risk Factors
EDAT- 2004/11/18 09:00
MHDA- 2005/04/06 09:00
CRDT- 2004/11/18 09:00
PHST- 2004/11/18 09:00 [pubmed]
PHST- 2005/04/06 09:00 [medline]
PHST- 2004/11/18 09:00 [entrez]
PST - ppublish
SO  - Int J Oncol. 2004 Dec;25(6):1769-80.